EUVIMEDEUVIMED entdecken
Crossref

Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome

Vita Dauksaite, Ali Tas, Falk Wachowius, Anouk Spruit, Martijn J van Hemert, Eric J Snijder, Eric P van der Veer, Anton Jan van Zonneveld iD

Nucleic Acid Therapeutics · 01.12.2023 · 33 (6) · 381-385

DOI: 10.1089/nat.2023.0012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 24.11.2023. Verfasst von Vita Dauksaite und 7 weiteren Autor:innen. Beteiligte Einrichtung: Einthoven Laboratory for Vascular and Regenerative Medicine, Department of Internal Medicine (Nephrology), Leiden University Medical Centre, Leiden, …. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused the current worldwide pandemic and the associated coronavirus disease 2019 with potentially lethal outcome. Although effective vaccines strongly contributed to reduce disease severity, establishing a toolbox to control current and newly emerging coronaviruses of epidemic concern requires the development of novel therapeutic compounds, to treat severely infected individuals and to prevent virus transmission. Here we present a therapeutic strategy targeting the SARS-CoV-2 RNA genome using antisense oligonucleotides (ASOs). We demonstrate that selected locked nucleic acid gapmers have the potency to reduce the in vitro intracellular viral load by up to 96%. Our promising results strongly support the case for further development of our preselected ASOs as therapeutic or prophylactic antiviral agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseCOVID-19HumansSARS-CoV-2RNA, ViralOligonucleotides

Stichwörter der Autor:innen

LNA gapmersSARS-CoV-2antisense oligonucleotidescoronaviruspositive-sense RNA virustherapeutic oligonucleotides

Substanzen

Oligonucleotides, AntisenseRNA, Virallocked nucleic acidOligonucleotides

Autor:innen und Institutionen

  • Einthoven Laboratory for Vascular and Regenerative Medicine, Department of Internal Medicine (Nephrology), Leiden University Medical Centre, Leiden, The Netherlands.
  • Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Hybridize Therapeutics, Oegstgeest, The Netherlands.

ORCID-Profile: Anton Jan van Zonneveld

Zitieren

APA

Dauksaite, V., Tas, A., Wachowius, F., Spruit, A., van Hemert, M. J., Snijder, E. J., van der Veer, E. P., & van Zonneveld, A. J. (2023). Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome. Nucleic Acid Therapeutics, 33(6), 381-385. https://doi.org/10.1089/nat.2023.0012

Vancouver

Dauksaite V, Tas A, Wachowius F, Spruit A, van Hemert MJ, Snijder EJ, et al. Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome. Nucleic Acid Therapeutics. 2023;33(6):381-385. doi:10.1089/nat.2023.0012

BibTeX
@article{Dauksaite2023,
  author = {Dauksaite, Vita and Tas, Ali and Wachowius, Falk and Spruit, Anouk and van Hemert, Martijn J and Snijder, Eric J and van der Veer, Eric P and van Zonneveld, Anton Jan},
  title = {Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome},
  journal = {Nucleic Acid Therapeutics},
  year = {2023},
  volume = {33},
  number = {6},
  pages = {381--385},
  doi = {10.1089/nat.2023.0012}
}
Kostenlos starten →